alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
sr UNITED STATES ENVIRONMENTAL PROTECTION AGENCY $

REGIONIX14c:s

75 Hawthorne Street San Francisco, CA 94105.3901 MAR152013 Samuel B. Boxerman Lisa E. Jones James R. Wedeking Sidley Austin LLP 1501 K Street, NW Washington, DC 20005 Thomas Woodworth NV Energy 6226 West Sahara Avenue Las Vegas, Nevada 89146 Dear Mr. Boxerman, Ms. Jones, Mr. Wedeking, and Mr. Woodworth: The U.S. Environmental Protection Agency has considered the petition yousubmitted onOctober 19, 2012, asking the agencytoreconsider

a single provision
in ourfinal rule related tothe compliance date for the Best Available Retrofit Technology determination for Reid Gardner Generating Station, published
in the Federal Register on August 23, 2012, entitled, “Approval and Promulgation
of Air Quality Implementation Plans; Nevada; Regional Haze State and Federal Implementation Plans; BART Determination for Reid Gardner Generating Station,” (77 FR 50936). As indicated
in your petition, EPA proposed, onApril 12, 2012, to require compliance within five yearsfrom promulgation
of the final rule with emission limits for nitrogen oxides established

asBART (77FR 21896). Based oncommentswereceived during the public comment period, EPA’s final rule required compliance with BART emission limits by January

1, 2015. Pursuant toClean Air Action section 307(d)(7)(B), EPA is granting reconsideration

of the compliance date in the final rule in order toallow for public commentonthe issue raised in your petition. Accordingly, today, the Acting Administrator has signed

anotice of proposed rulemaking that will he published
in the Federal Register addressing the date by which Units
1, 2, and
3 atReid Gardner Generating Station must comply with emission limits for NO established

asBART. If youhave any questions regarding the reconsideration process, please contactAnn Lyons at (415) 972-3883 or Matthew Marks at (202) 564-3276. We thank youfor yourcontinued interest in this rule and look forward to hearing from you during the reconsideration process. Sincerely, Jared Blumenfei PnnedonRetyckd Paper
# C_2009055EN.01004301.xml

| 7.3.2009 | EN | Official Journal of the European Union | C 55/43 |
| --- | --- | --- | --- |

7.3.2009

EN

Official Journal of the European Union

C 55/43

---

Action brought on 22 December 2008 — 4care v OHIM — Laboratorios Diafarm (Acumed)

(Case T-575/08)

(2009/C 55/76)

Language in which the application was lodged: German

Parties

Applicant: 4care AG (Kiel, Germany) (represented by: S. Redeker, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM: Laboratorios Diafarm, SA (Barbera del Valles, Spain)

Other party to the proceedings before the Board of Appeal of OHIM:

Form of order sought

| — | Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 7 October 2008 in Case R 16636/2007-2 and reject the opposition entered by Laboratorios Diafarm, SA; |
| --- | --- |

—

Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 7 October 2008 in Case R 16636/2007-2 and reject the opposition entered by Laboratorios Diafarm, SA;

| — | order the defendant and Laboratorios Diafarm, SA to pay the costs. |
| --- | --- |

—

order the defendant and Laboratorios Diafarm, SA to pay the costs.

Pleas in law and main arguments

Applicant for a Community trade mark: The applicant.

Applicant for a Community trade mark:

Community trade mark concerned: Figurative mark ‘Acumed’ for goods in Classes 3, 5 and 9 (application for registration No 4493136).

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: Laboratorios Diafarm, SA.

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: Spanish word mark ‘AQUAMED ACTIVE’ (trade mark No 2506452) for goods in Class 5 and Community word mark ‘AQUAMED ACTIVE’ (No 2882272) for goods in Class 5.

Mark or sign cited in opposition:

Decision of the Opposition Division: Opposition allowed.

Decision of the Opposition Division:

Decision of the Board of Appeal: Appeal dismissed.

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) of Regulation (EC) No 40/94 (1), since there is no likelihood of confusion between the marks at issue.

Pleas in law:

1

---

(1)  Council Regulation (EC) No 40/94 of 20 December 1993 on the Community trade mark (OJ 1994 L 11, p. 1).

1

---
#### Barbara Paciella, Respondent, v Frank Paciella, Appellant.

(Appeal No. 1.)

— Appeal unanimously dismissed without costs. Memorandum: The support order appealed from was entered upon consent of the parties. Respondent’s appropriate remedy is to move to vacate or resettle the order *(see, Matter of Colletti v Colletti,*56 AD2d 845). (Appeal from Order of Suffolk County Family Court, McNulty, J. — Child Support.) Present — Dillon, P. J., Doerr, Boomer, Pine and Lawton, JJ.
EXHIBIT 32.2




CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002






In connection with the Quarterly Report of Reed’s, Inc. (the "Company") on Form 10-Q for the period ending March 31, 2011 as filed with the U.S. Securities and Exchange Commission on the date hereof (the "Report"), I, James Linesch, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:






(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and






(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.











Dated:  May 11, 2011









/s/ James Linesch


James Linesch


Chief Financial Officer


(Principal Financial Officer)
COURT OF APPEALS FOR THE

FIRST DISTRICT OF TEXAS AT HOUSTON

ORDER WITHDRAWING MEDIATION ORDER

Court of Appeals Number: 01-21-00144-CV

Style: Baldomero Ortiz v. Adenrele Olandapo-Jimoh & The Law Firm of 

Jimoh, P.C.

Trial Court Case Number: 2020-00394

Trial Court: 234th District Court of Harris County

Type of Motion: Objection to Mediation

Party Filing Motion: Appellee

Appellee has objected to mediation. The Court’s mediation order dated April 7, 

2021 is withdrawn.

Judge's signature: /s/ Peter Kelly

 Acting individually 

Date: April 13, 2021

* Absent emergency or a statement that the motion is unopposed, must wait ten days before acting on motion except for 

motion to extend time to file a brief. See TEX. R. APP. P. 10.3(a).

Note: Single justice may grant or deny any request for relief properly sought by motion, except in a civil case a single justice 

should not: (1) act on a petition for an extraordinary writ or (2) dismiss or otherwise determine an appeal or a motion for 

rehearing. TEX. R. APP. P. 10.4(a).
Print, cut, laminate, and use to jog your memory with key steps for eTRAP field use.

eTRAP Login

• Ensure internet connection

• Enter eAuth username and password

Downloading Books

• Ensure no books are already checked out (make sure trap books is not blue hyperlinked)

• Go to “Get Books”

• Select your office

• Check the boxes of the books to download

• Click “Download”

Returning Books

• Ensure internet connection

• Go to “Return Books”

• Select the book to return

• Review the information then click “Return Book”

Placing a Trap in a “New Grid”

• Click “Trap Sites”

• Click “Place Traps”
Print, cut, laminate, and use to jog your memory with key steps for eTRAP field use.

Placing a Trap in a “Existing Grid”

• Ensure you are in the correct book/grid

• Click “More...” in the bottom right corner

• Click “Place Trap(s)”

• Select a new or existing trap site

Entering Trap Information

• Type in the grid you are in (remember dashes)

• Enter the trap number and letter

• Enter the trap name

• Select the county then town

• Select the trap type, then host type, then survey type

• Click “Place”

Setting/Re-setting GPS Coordinates

• Click the red (or green if there are already coordinates) maps place mark symbol

• Select “Manual” if you would like to type in the latitude and longitude yourself

• Select “Yes” if you would like to take the latitude and longitude of the location you are 

currently standing

Note: Ensure Google Maps is open and that you toggle between google maps and eTRAP before 

getting the coordinates in eTRAP

Entering/Editing Notes

• Click the notepad icon

• Enter the notes you would like to associate with this trap location

• Click “Back” in the upper left corner
Print, cut, laminate, and use to jog your memory with key steps for eTRAP field use.

Edit Address/Trap Name Information

• Click “More...” in the bottom right

• Select “Correct address of ...”

• Enter the new name/address of the trap

Performing Trapping Actions

• Ensure you have the trap you want to perform the action on selected

• Click “Perform Activities”

• Click “Select” under the “Action” column

• Select the Action you would like to perform

• Press “Back” in the upper left corner

Adding Servicing Notes

• Once you have selected the action, click the notepad symbol in the bottom right corner of 

the same box

• Type in the notes you would like to associate with that servicing

• Click the trap name in the upper left corner to save

Show Retired Trap Sites

• Click “More...” in the bottom right corner

• Click “Show Retired Trap Sites”
Print, cut, laminate, and use to jog your memory with key steps for eTRAP field use.

Battery Saving Mode

• Go to Settings

• Slide the button to the right so that it shows green to ensure Airplane Mode is on

Improving GPS Accuracy

• Open google Maps

• Before placing a trap and/or when searching for a trap, minimize eTRAP and go to Google 

Maps

• Allow a few seconds for the GPS to sync

• Minimize Google Maps then go back to eTRAP

• Ensure the blue tracker on the eTRAP map screen re-orients itself

• Repeat when necessary
**Exhibit 32.1**

 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003**

 

In connection with the Quarterly Report of Alliance Bancshares California (the “Company”) on Form 10-QSB for the period ending March 31, 2004 asfiled with the Securities and Exchange Commission on the date hereof (the “Report”), I, Curtis S. Reis, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 ofthe Sarbanes-Oxley Act of 2003, that: 

 

(1) The Report fullycomplies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: May 7, 2004 

**Exhibit 32.2**

 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003**

 

In connection with the Quarterly Report of Alliance Bancshares California (the “Company”) on Form 10-QSB for the period ending March 31, 2004 asfiled with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel L. Erickson, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adoptedpursuant to § 906 of the Sarbanes-Oxley Act of 2003, that: 

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Daniel L. Erickson

Executive Vice President

Chief Financial Officer

 

Date: May 7, 2004
# C_2008236EN.01001502.xml

| 13.9.2008 | EN | Official Journal of the European Union | C 236/15 |
| --- | --- | --- | --- |

13.9.2008

EN

Official Journal of the European Union

C 236/15

---

Action brought on 15 July 2008 — Bayer Healthcare v OHIM — Laboratorios ERN (CITRACAL)

(Case T-277/08)

(2008/C 236/26)

Language in which the application was lodged: English

Parties

Applicant: Bayer Healthcare LLC (Morristown, United States) (represented by: M. Edenborough, barrister)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Laboratorios ERN, SA (Sant Just Desvern, Spain)

Other party to the proceedings before the Board of Appeal:

Form of order sought

| — | Annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 5 May 2008 in case R 459/2007-4; and |
| --- | --- |

—

Annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 5 May 2008 in case R 459/2007-4; and

| — | Order the defendant or alternatively the other party to the proceedings before the Board of Appeal to pay the costs. As a further alternative, to order the defendant and the other party to the proceedings before the Board of Appeal to be liable jointly and severally for the costs. |
| --- | --- |

—

Order the defendant or alternatively the other party to the proceedings before the Board of Appeal to pay the costs. As a further alternative, to order the defendant and the other party to the proceedings before the Board of Appeal to be liable jointly and severally for the costs.

Pleas in law and main arguments

Applicant for the Community trade mark: The applicant (formerly Mission Pharmacal Company)

Applicant for the Community trade mark:

Community trade mark concerned: The word mark ‘CITRACAL’ for goods in class 5, application No 1 757 855

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: The other party to the proceedings before the Board of Appeal (formerly Laboratorios Diviser-Aquilea, SL)

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited: Spanish trade mark registration No 223 532 of the mark ‘CICATRAL’ for goods in classes 1 and 5

Mark or sign cited:

Decision of the Opposition Division: Uphold the opposition with respect to all the contested goods

Decision of the Opposition Division:

Decision of the Board of Appeal: Dismissal of the appeal

Decision of the Board of Appeal:

Pleas in law: The Board of Appeal erred in its assessment of the evidence of proof-of-use, and in particular on the issue of the provision of a suitable translation of the goods in relation to which the mark cited in the opposition proceedings was used. Further, the Board of Appeal erred in its assessment of the existence of a likelihood of confusion between the conflicting trade marks.

Pleas in law:

---
```

[Congressional Record Volume 158, Number 123 (Thursday, September 13, 2012)]
[House]
[Page H6001]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

           By Mr. SAM JOHNSON of Texas:
       H.J. Res. 120.
       Congress has the power to enact this legislation pursuant 
     to the following:
       Article 1, Section 8, Clause 17, giving Congress exclusive 
     jurisdiction over the District of Columbia. That clause was 
     cited as the authority for the government's ability to accept 
     the original Smithson donation and the creation of the 
     Smithsonian Institution via the Act of August 10, 1846.
       Article 1, Section 8, Clause 18, the Necessary and Proper 
     clause, which provides the power to enact legislation 
     necessary to effectuate one of the earlier enumerated powers, 
     such as the authority granted in Article 1, Section 8, Clause 
     17 referred to bove.

                          ____________________
```
EXHIBIT 99.2

                   CERTIFICATION OF PERIODIC FINANCIAL REPORTS
                       PURSUANT TO 18 U.S.C. SECTION 1350


Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, the undersigned officer of Armkel, LLC (the
"Company") certifies to her knowledge that:

(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period
ended June 27, 2003 fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in that Form 10-Q fairly presents, in all material
respects, the financial conditions and results of operation of the Company.



August 8, 2003                             /s/ Maureen Usifer
------------------------------             ------------------------------------
Date                                       Maureen Usifer
                                           Chief Financial Officer




A signed original of this written statement required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement
required by Section 906, has been provided to Church & Dwight Co., Inc. and will
be retained by Church & Dwight Co., Inc. and furnished to the Securities and
Exchange Commission or its staff upon request.
# C_2010274EN.01003201.xml

| 9.10.2010 | EN | Official Journal of the European Union | C 274/32 |
| --- | --- | --- | --- |

9.10.2010

EN

Official Journal of the European Union

C 274/32

---

Judgment of the Civil Service Tribunal (Third Chamber) of 1 July 2010 — Füller-Tomlinson v European Parliament

(Case F-97/08) (1)

1

(Civil service - Former member of the temporary staff - Occupational disease - Physical or mental harm - Duration of the procedure for the recognition of the occupational nature of the disease)

2010/C 274/48

Language of the case: French

Parties

Parties

Applicant: Paulette Füller-Tomlinson (Belgium) (represented by: L. Levi, lawyer)

Applicant:

Defendant: European Parliament (represented by: K. Zejdová and S. Seyr, acting as Agents)

Defendant:

Re:

Re:

Annulment of the decision establishing the part of the partial permanent invalidity attributable to the occupational nature of a disease affecting the applicant at 20 %, as well as, in the alternative, an order against the defendant to pay a sum in damages for the non-material damage suffered by the applicant.

Operative part of the judgment

Operative part of the judgment

The Tribunal:

| 1. | Dismisses the application; |
| --- | --- |

1.

Dismisses the application;

| 2. | Orders Ms Füller-Tomlinson to bear all the costs. |
| --- | --- |

2.

Orders Ms Füller-Tomlinson to bear all the costs.

---

(1)  OJ C 44, 21.2.2009, p. 76.

1

---
1 of 2 

Preservatives in Biologics Manufacture 

Overview

The purpose of this chapter is to outline the policy of the Center for Veterinary Biologics 

regarding preservative use in veterinary biologics. Applicable regulations and guidance are 

found in: 

• 9CFR 114.10 

• 9CFR 112.2(a)(10) 

• 9CFR 113.100(f) 

• 9 CFR 113.200(f) 

• VS Memorandum 800.206 

Background

The regulations consider any antibiotic to be a preservative, and the CVB includes in this 

definition antibiotics added to the production media or at any subsequent stage of the 

manufacturing process. 9CFR 114.10 specifies the maximum permissible amounts and 

combinations of antibiotics authorized for use as preservatives in veterinary biological products. 

The maximum allowable concentrations of antibiotics listed are expected to inhibit growth of 

common susceptible bacterial contaminants, and a definite genetic determinant for resistance 

would be necessary for survival at these concentrations. These levels are also below a 

therapeutic dose for the animal receiving a dose of the biological product. 

Antibiotics used in virus seed stock purification are not restricted as to the kind or amounts, 

provided carryover into the final product is controlled and specified in the Outline of Production. 

The CVB considers carryover to be controlled if the antibiotics used in seed stock purification 

are added to the seed stock culture in concentrations no greater than generally accepted 

inhibitory levels for susceptible contaminants and/or the resultant culture media is decanted. 

One permitted combination includes penicillin and streptomycin. Penicillin and streptomycin are 

commonly used in combination to minimize contamination in the laboratory. Penicillin 

interferes with bacterial cell wall synthesis while streptomycin inhibits bacterial protein 

synthesis. Through these different mechanisms of action, the combination of the two antibiotics 

acts against a broad spectrum of bacteria. 

Another permitted combination includes either amphotericin B or nystatin with one of the other 

antibiotics listed. Amphotericin B and nystatin are both antifungal agents that affect membrane 

permeability. Allowing one of these agents to be used with the other permitted antibiotics 

generates a preservative that is effective against a broader spectrum of organisms, but allowing 

both to be used in the same product would be of little benefit. Amphotericin B or nystatin may 

also be used with a combination of polymyxin B and neomycin, or with the 

penicillin/streptomycin combination. Polymyxin B (a cationic polypeptide) and neomycin (an
EXHIBIT 32.2
                            CERTIFICATION PURSUANT TO
                                 18 U.S.C. 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly  Report of UNITECH ENERGY CORP. (the "Company")
on Form 10-QSB for the period ended April 30, 2004, as filed with the Securities
and Exchange  Commission on the date hereof (the  "Report"),  I, James  Durward,
Chief Executive Officer of the Company,  certify, pursuant to 18 U.S.C. 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and

The  information  contained  in the  Report  fairly  presents,  in all  material
respects, the financial condition and results of operations of the Company.


                                                   /s/ James Durward
                                                   --------------------------
Date: March 28, 2005                                   James Durward
                                                       Chief Executive Officer
EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of NB&T Financial Group, Inc. (the Company), on
Form 10-K for the period ended December 31, 2007, dated the date of this Certification (the Report), I, John J. Limbert, the President and the Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report complies with the
requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



|                    |  |  |  |                                      
|------------------- |  |  |  | -------------------------------------
|Date:March 18, 2008 |  |  |  | /s/    JOHN J.
LIMBERT               
|                    |  |  |  | John J. Limbert                      
|                    |  |  |  | President and Chief Executive Officer



71